[go: up one dir, main page]

BRPI0820218A2 - Inibição de receptor de proteína estimuladora de macrófagos (ron) e métodos de tratamento dos mesmos - Google Patents

Inibição de receptor de proteína estimuladora de macrófagos (ron) e métodos de tratamento dos mesmos

Info

Publication number
BRPI0820218A2
BRPI0820218A2 BRPI0820218-4A BRPI0820218A BRPI0820218A2 BR PI0820218 A2 BRPI0820218 A2 BR PI0820218A2 BR PI0820218 A BRPI0820218 A BR PI0820218A BR PI0820218 A2 BRPI0820218 A2 BR PI0820218A2
Authority
BR
Brazil
Prior art keywords
ron
inhibition
treatment
methods
protein receptor
Prior art date
Application number
BRPI0820218-4A
Other languages
English (en)
Inventor
Daniel Pereira
Jennifer O'toole
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820218(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of BRPI0820218A2 publication Critical patent/BRPI0820218A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0820218-4A 2007-11-21 2008-11-21 Inibição de receptor de proteína estimuladora de macrófagos (ron) e métodos de tratamento dos mesmos BRPI0820218A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98955807P 2007-11-21 2007-11-21
PCT/US2008/013130 WO2009070294A2 (en) 2007-11-21 2008-11-21 Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof

Publications (1)

Publication Number Publication Date
BRPI0820218A2 true BRPI0820218A2 (pt) 2015-06-23

Family

ID=40364492

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820218-4A BRPI0820218A2 (pt) 2007-11-21 2008-11-21 Inibição de receptor de proteína estimuladora de macrófagos (ron) e métodos de tratamento dos mesmos

Country Status (20)

Country Link
US (2) US7947811B2 (pt)
EP (1) EP2222703A2 (pt)
JP (1) JP5324593B2 (pt)
KR (1) KR101227338B1 (pt)
CN (1) CN101868478B (pt)
AR (1) AR069393A1 (pt)
AU (1) AU2008330089B2 (pt)
BR (1) BRPI0820218A2 (pt)
CA (1) CA2706583A1 (pt)
CL (1) CL2008003449A1 (pt)
EA (1) EA018717B1 (pt)
IL (1) IL204743A (pt)
MX (1) MX2010005651A (pt)
NZ (1) NZ584271A (pt)
PA (1) PA8804901A1 (pt)
PE (1) PE20091713A1 (pt)
TW (1) TWI417106B (pt)
UA (1) UA99633C2 (pt)
UY (1) UY31478A1 (pt)
WO (1) WO2009070294A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
CA2712697A1 (en) * 2008-01-22 2009-07-30 Biogen Idec Ma Inc. Ron antibodies and uses thereof
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
HUE029257T2 (en) * 2009-12-29 2017-02-28 Aptevo Res And Dev Llc Heterodimer binding proteins and their use
AR082194A1 (es) 2010-07-06 2012-11-21 Aveo Pharmaceuticals Inc Anticuerpos anti-ron
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CA2833785C (en) * 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
HK1212998A1 (zh) * 2012-11-30 2016-06-24 F. Hoffmann-La Roche Ag Ron组合物及其使用方法
EP2961772A1 (en) * 2013-02-26 2016-01-06 Roche Glycart AG Anti-mcsp antibodies
JP2016510755A (ja) 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
EP3176268B1 (en) * 2014-07-29 2019-07-17 Wellmarker Bio Co., Ltd. Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
ES2876232T3 (es) * 2014-09-03 2021-11-12 Wellmarker Bio Co Ltd Biomarcador para predecir la sensibilidad al inhibidor de proteína quinasa y uso de este
SG10201913858WA (en) * 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2018052789A1 (en) 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
US20250188154A1 (en) * 2020-09-15 2025-06-12 Duke University Coronavirus antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2180535T3 (es) 1991-02-22 2003-02-16 American Cyanamid Co Identificacion de un nuevo gen de tirosina quinasa receptora humana.
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1311291A4 (en) 2000-08-09 2007-07-25 Imclone Systems Inc TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
SE518548C2 (sv) 2001-04-11 2002-10-22 Sca Hygiene Prod Ab Absorberande alster med förbättrad diskretion
US7235523B2 (en) 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1916001B1 (en) 2002-03-04 2011-05-25 Imclone LLC Human antibodies specific to KDR and uses thereof
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US20090246205A1 (en) * 2004-05-13 2009-10-01 Imclone Systems, Inc Inhibition of macrophage-stimulating protein receptor (ron)

Also Published As

Publication number Publication date
US7947811B2 (en) 2011-05-24
UY31478A1 (es) 2009-07-17
JP2011504176A (ja) 2011-02-03
AU2008330089A1 (en) 2009-06-04
MX2010005651A (es) 2010-06-11
EP2222703A2 (en) 2010-09-01
KR20100074293A (ko) 2010-07-01
EA018717B1 (ru) 2013-10-30
CL2008003449A1 (es) 2010-02-19
CN101868478B (zh) 2013-11-13
PE20091713A1 (es) 2009-11-13
TWI417106B (zh) 2013-12-01
TW200936161A (en) 2009-09-01
AU2008330089B2 (en) 2013-09-05
US20110135631A1 (en) 2011-06-09
CN101868478A (zh) 2010-10-20
WO2009070294A2 (en) 2009-06-04
IL204743A0 (en) 2010-11-30
NZ584271A (en) 2012-05-25
WO2009070294A3 (en) 2009-08-20
US8133489B2 (en) 2012-03-13
EA201070636A1 (ru) 2010-10-29
JP5324593B2 (ja) 2013-10-23
AR069393A1 (es) 2010-01-20
KR101227338B1 (ko) 2013-01-28
UA99633C2 (ru) 2012-09-10
US20090136510A1 (en) 2009-05-28
IL204743A (en) 2013-10-31
PA8804901A1 (es) 2009-06-23
CA2706583A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
BRPI0820218A2 (pt) Inibição de receptor de proteína estimuladora de macrófagos (ron) e métodos de tratamento dos mesmos
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
SMT201600080B (it) Inibitori di chinasi janus per il trattamento di occhio secco e altre malattie oculari
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
LT2240135T (lt) Prietaisas nutukimo ir reflukso ligos gydymui
DK3323815T3 (en) Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
BRPI1014864A2 (pt) "implante de processos espinhosos e métodos associados"
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
BRPI0820882A2 (pt) Dispositivos e métodos de estimulação de dermátomo
EP2019667A4 (en) DETECTION AND IMAGING OF TARGET TISSUE
BRPI0923283A2 (pt) conjugados terapêuticos de peptídeo e usos dos mesmos
DK2041129T3 (da) Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0810094A2 (pt) Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
IL201309A0 (en) Novel n - (8 - heteroaryltetrahydronaphtalene - 2yl) or n - (5 - heteroarylchromane - 3 - yl) carboxamide derivatives for the treatment of pain
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
BRPI0821779A2 (pt) tratamento terapêutico de câncer
PT2046324T (pt) Tratamento e prevenção de mucosite por derivados de antocianidina
BRPI0719519A2 (pt) Sistemas de descarga e métodos de utilização dos mesmos
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
BRPI0906867A2 (pt) inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo
DK2310003T3 (da) Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv
ES2315959T5 (es) Dispositivo y sistema médico para la estimulación eléctrica de la osteogénesis
BRPI0715728A8 (pt) tratamento de distúrbios cartilaginosos
EP2164517A4 (en) INHIBITION OF IL-18 AND PROTEIN KINASE R IN THE TREATMENT OF OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.